-
Trial of Nebulized CF Candidate Completes Single-ascending Dosing
The RESTORE-CF trial, investigating Translate Bio’s nebulized therapy MRT5005, has completed the single-ascending dose regimen in patients with CF. Read more about the trial and its results here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.